Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOMINATE trial in locally advanced rectal cancer
jRCTs051200121Phase 2Recruiting
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine, oxaliplatin and bevacizumab in rectal adenocarcinoma (2 arms). Primary endpoint: Rate of pCR and cCR at 2 years or longer. Started Mar 2021; status: recruiting.
02
Drugs
capecitabineoxaliplatinbevacizumab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on jRCTs051200121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200121.